BioSpace

Lilly pens another deal, inking up to $5.9B oncology pact with Stipple

A licensing pact with Stipple Bio was one of two announced by Eli Lilly on Monday, after the up to $1.5 billion buyout of blood cancer-focused Calytrix Bio.

By BioSpace

1 min read
Lilly pens another deal, inking up to $5.9B oncology pact with Stipple
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights